Argenx’s Next Blockbuster? Stock Jumps 12% After Phase 3 Myositis Trial Hits Key Goal
Argenx stock surges 12% as VYVGART Hytrulo hits Phase 3 ALKIVIA endpoint in autoimmune myositis, showing strong 52-week clinical efficacy.
Argenx's new medicine passed an important test, showing it helps people with a muscle disease. When medicines work well in testing, people get excited about the company's future, which is why the stock price went up.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.